Session Type
Meeting
Search Results for Opioid
Oral Presentations
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Despite a public health crisis – over 500,000 individuals have died from opioid overdoses since 2000 – and the availability of effective therapies, most patients with Opioid Use Disorder (OUD) are not offered treatment. Medication-Assisted Treatment (MAT), such as with buprenorphine, is associated with significantly higher rates of abstinence and follow-up, lower rates of […]
Oral Presentations
Abstract Number: Oral
SHM Converge 2021
Background: Despite evidence that the use of medications for patients with opioid use disorder (OUD) leads to reduced mortality and improved engagement in outpatient addiction treatment, these life-saving medications are underutilized in the hospital setting. This study reports the outcomes of a hospitalist-led interprofessional and multidisciplinary inpatient program, known as the B-Team (buprenorphine team), to […]
Oral Presentations
Abstract Number: Oral
Hospital Medicine 2020, Virtual Competition
Background: There were approximately 46,000 opioid overdose deaths in 2017. It is known that opioid overdose risk is increased in patients with a diagnosis of substance use disorder, prior opioid overdose, and high suspicion of risk as assessed by clinical teams. The Risk Index for Overdose or Serious Opioid-Induced Respiratory Depression (RIOSORD) is a validated […]
Oral Presentations
Abstract Number: Oral
Hospital Medicine 2020, Virtual Competition
Background: Prior studies have found racial disparities in how patients are assessed for pain and prescribed opioids from emergency department and surgical settings. However, we do not know whether similar disparities exist among general medicine inpatients. We examined opioid prescriptions at discharge among adults admitted to the general medicine service at our medical center, with […]
Oral Presentations
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Despite a public health crisis – over 500,000 individuals have died from opioid overdoses since 2000 – and the availability of effective therapies, most patients with Opioid Use Disorder (OUD) are not offered treatment. Medication-Assisted Treatment (MAT), such as with buprenorphine, is associated with significantly higher rates of abstinence and follow-up, lower rates of […]
Abstract Number: 35
SHM Converge 2023
Background: The American opioid epidemic is a public health emergency, with over 100,000 opioid-related overdose deaths occurring in 2021 (1). Harm reduction treatment models, formulated with the goal of reducing the negative consequences of opioid use, have been implemented as an alternative approach in minimizing opioid overdose and mortality (2). With approximately 4-11% of hospitalized […]
Abstract Number: 59
SHM Converge 2021
Background: Methylnaltrexone (MNTX) is a peripherally acting µ-opioid receptor antagonist indicated for opioid-induced constipation (OIC), which can be a serious consequence of opioid analgesia. We evaluated whether baseline osmotic agent (eg, milk of magnesia, polyethylene glycol, lactulose, sorbitol) or stimulant (eg, senna, bisacodyl) use affects the efficacy and safety of MNTX among a subgroup of […]
Abstract Number: 83
Hospital Medicine 2020, Virtual Competition
Background: The US has a heavy burden of deaths from opioid overdoses, and New Mexico is not excepted from this. Treatment options for opioid use disorder (OUD) are buprenorphine/naloxone (“Suboxone”), methadone, naltrexone, counseling, and/or behavioral therapy. Long-acting oral opioids like Suboxone, are the most effective methods for treating opioid withdrawal and OUD. They are often […]
Abstract Number: 87
Hospital Medicine 2016, March 6-9, San Diego, Calif.
Background: Pain remains a major concern for medically hospitalized adults, and pain treatment is a focus of hospital quality reporting and improvement efforts. Pharmacologic treatment during hospitalization for acute pain and cancer pain rest on some evidence, but as many as 1 in 3 adult medical inpatients suffer from chronic pain. Little is known about […]
Abstract Number: 98
SHM Converge 2021
Background: Prior case reports and case-series reports have shown an association between Opioid use disorder and Thrombotic Thrombocytopenic Purpura (TTP). However, clinical data regarding Thrombotic Thrombocytopenic Purpura co-existing with Opioid use disorder are still lacking in the literature. We aim to study patient characteristics, epidemiology, co-morbidities, and clinical outcomes in these patients. Methods: We analyzed […]